Incyte Pharmaceuticals Inc., Novo Nordisk deal

Novo Nordisk and its ZymoGenetics subsidiary secured access to Lifeseq, IPI's DNA sequence and gene expression database. Novo Nordisk (Denmark) will pay undisclosed database access fees, and milestones and royalties on products developed using IPI's technology.

IPI (Palo Alto) said the fees are consistent with those of its other two database customers, The Upjohn Co. and Pfizer. In 1994, Upjohn purchased $10 million worth of IPI common stock and paid a $10 million licensing fee for non-exclusive access to Lifeseq. In 1993, Pfizer bought $9.05 million worth of IPI common stock and paid $15.75 million in research funding and database access charges. ...